Measuring Urinary Collagen Cross-Links in Breast Cancer Treatment
Author Information
Author(s): Walls J, Assiri A, Howell A, Rogers E, Ratcliffe W A, Eastell R, Bundred N J
Primary Institution: Department of Surgery, University Hospital of South Manchester
Hypothesis
Can urinary collagen cross-links predict response to therapy in breast cancer patients with bone metastases earlier than traditional methods?
Conclusion
Urinary cross-link measurements can provide an earlier and more objective assessment of treatment response in breast cancer patients with bone metastases.
Supporting Evidence
- Seventeen women responded to hormonal therapy, while 19 developed progressive disease.
- Both Pyr and Dpyr increased in women with progressive disease, with changes becoming apparent by 8 weeks.
- Urinary cross-link measurements were more sensitive and specific than the standard serum tumour marker CA 15-3.
Takeaway
Doctors can check special markers in urine to see if breast cancer treatment is working faster than using scans.
Methodology
Measured pyridinoline and deoxypyridinoline cross-links in urine of breast cancer patients with bone metastases to assess treatment response.
Participant Demographics
36 breast cancer patients with bone metastases, including 17 who responded to therapy and 19 who had progressive disease.
Statistical Information
P-Value
<0.03
Statistical Significance
p<0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website